WHO Consultation on Considerations for Regulatory Expectations of Zika Vaccines for use during an Emergency
Starling Geneva Hotel & Conference Center, Geneva, Switzerland
6 to 7 June 2016

LIST OF PARTICIPANTS

PARTICIPANTS

Jesus Barral-Guerin, Senior Contract Manager, New Vaccines, Vaccine Centre, UNICEF Supply Division, Copenhagen, Denmark

Alan Barrett, Director, Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas, USA

Luciana Borio, Acting Chief Scientist, Office of the Chief Scientist, Food and Drug Administration, Silver Spring, Maryland, USA

Rick Bright, Director - Influenza Division, Biomedical Advanced Research & Development Authority (BARDA), US Department of Health and Human Services (HHS), Washington DC, USA

Marco Cavaleri, Executive Director & Head, Anti-Infectives and Vaccines, European Medicines Agency London, UK

Alejandro Cravioto, Senior Epidemiologist, Precision Global Health, Seattle, WA, USA

Marcos da Silva Freire, Vice Director, Technological Development, Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil

Anna Durbin, Associate Professor, International Health, Global Disease Epidemiology and Control, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA (via telephone)

Bruno Zago França Diniz, Specialist, Regulation and Health Surveillance, Clinical Trial Evaluation Department, National Health Surveillance Agency, Brasilia, Brazil

Theresa Finn, Associate Director of Regulatory Policy, Office of Vaccines Research and Review, Centre for Biologics Evaluation and Research, Rockville, MD, USA

Barney Graham, Deputy Director, Vaccine Research Center, Chief, Viral Pathogenesis Laboratory and Translational Science Core, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA

Heather Greenstone, Program Officer, Virology Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Rockville, MD, USA
Elwyn Griffiths, Consultant, Chair ECBS, Surrey, UK

Akira Homma, Senior Scientific Adviser, Bio-Manguinhos / Fiocruz, BioManguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

Philipp Kalpaxis, Contract Specialist, New Vaccines, Vaccine Centre, UNICEF Supply Division, Copenhagen, Denmark

David Kaslow, Vice President, Product Development, PATH, Seattle, WA, USA

Maria de la Luz Lara Mendez, Director of Marketing Authorization, Commission on Sanitary Authorization, Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), Del. Benito Juarez, Mexico

Hilary Marston, Medical Officer, Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA

Heidi Meyer, Viral Vaccines Section, Paul-Ehrlich-Institut, Langen, Germany

Karen Midthun, Consultant, Sharpsburg, MD, USA

Kayvon Modjarrad, Associate Director, Emerging Infectious Disease Threats, Military HIV Research Program, Walter Reed Army Institute of Research, Bethesda, USA

Mark Page, Principal Scientist, Division of Virology, National Institute of Biological Standards & Control, Herts, UK

Laura Rodrigues, Taught Course Director ITD, Professor in Communicable Disease Epidemiology, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK

Tom Solomon, Director - Institute of Infection and Global Health; Chair of Neurological Science; Head - Brain Infections Group, MRC Senior Clinical Fellow, University of Liverpool and Walton Centre for Neurology and Neurosurgery, University of Liverpool, Institute of Infection and Global Health, Liverpool, UK

Douglas Wassenaar, Professor, School of Psychology, University of KwaZulu-Natal, Durban, South Africa

Pedro Vasconcelos, Research, Arbovirology and Hemorrhagic Fevers, Instituto Evandro Chagas/SVS/MS, Belem, Brazil

Matthew Lim, Deputy Health Attaché, Permanent Mission of the United States of America to the United Nations Office and other International Organizations at Geneva, Chambésy, Switzerland

Robert Walker, Director, Division of Clinical Studies, Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA), Washington DC, USA
OBSERVERS

James Cummings, Senior Director, Clinical Development, Novavax Inc., Gaithersburg, MD, USA

Lawrence Ellingsworth, Vice President, Development Operations, Novavax Inc., Gaithersburg, MD, USA

Gabriele Fabini, Senior Regulatory Affairs Specialist, Regulatory Affairs, Valneva Austria GmbH, Vienna, Austria

Christiane Gerke, Head of Vaccine Programs, Development Department/Grant Office, Institut Pasteur, Paris, France

Nicholas Jackson, Vice President, Head of Global Research, Sanofi Pasteur, Lyon, France

Maïna L'Azou, Epidemiologist, Global Epidemiology Department, Sanofi Pasteur, Lyon, France

Thomas Monath, Chief Scientific & Chief Operating Officer, BioProtection Systems, BioProtection Systems/NewLink Genetics Corporation, Devens, MA, USA

Alexander Precioso, Director, Clinical Trials and Pharmacovigilance Division, Instituto Butantan, São Paulo, Brazil

Taryn Rogalski-Salter, Vice President and Head, Global Regulatory Affairs Vaccines, Takeda Vaccines, Inc., Deerfield, IL, USA

Kandaswamy Sumathy, Director R&D, Bharat Biotech International Limited, Genome Valley, Hyderabad, India

Ted Tsai, Head Scientific Affairs and Policy, Takeda Chemicals Industries, Osaka, Japan

Michele Yelmene, Vice President, Clinical Operations, Regulatory Affairs, and Quality Assurance, Hawaii Biotech Inc., Aiea, Hawaii, USA

WHO SECRETARIAT

Godwin Enwere, Scientist, Prequalification Team, Regulatory Systems Strengthening, World Health Organization, Geneva, Switzerland

Birgitte Giersing, Technical Officer, Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland

Joachim Hombach, Senior Adviser, Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland
Raul Iraheta, Consultant, Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland

Olivier Lapujade, Scientist, Prequalification Team, Regulatory Systems Strengthening, World Health Organization, Geneva, Switzerland

Andrew Meek, Scientist, Prequalification Team, Regulatory Systems Strengthening, World Health Organization, Geneva, Switzerland


Kirsten Vannice, Scientist, Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland